Atea Pharmaceuticals (AVIR) Stock
Clinical stage biotech developing oral antiviral treatments. Here's the price, business snapshot, and what's worth knowing about Atea Pharmaceuticals in July 2026.
Atea Pharmaceuticals Inc (ticker AVIR) is a clinical-stage biopharmaceutical company focussed on developing oral antiviral therapies targeting RNA viruses. With a market capitalisation of about $261.09 million, Atea operates at the development end of the biotech spectrum: value drivers include clinical trial results, regulatory decisions, partnership or licensing deals, and potential commercial prospects. As a clinical-stage company it typically generates limited product revenue and relies on financing, collaborations and milestone payments to fund research and operations. Shares can be volatile around trial readouts and regulatory news. Key risks include clinical failure, regulatory rejection, competitive pressure and potential dilution from future fundraising. This summary is educational and not personalised advice; investors should consider their risk tolerance, review company filings, and may wish to consult a regulated financial adviser. Small-cap biotech investments are generally more suitable for those who can accept high volatility and the possibility of losing their capital.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Atea Pharmaceuticals' stock with a target price of $2, indicating growth potential.
Financial Health
Atea Pharmaceuticals is performing well, showing strong cash flow and solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring AVIR
Next-Gen Hepatic Therapeutics | Basket Overview
The FDA has granted Gilead Sciences approval for the first-ever treatment targeting chronic hepatitis delta virus. This landmark regulatory decision paves the way for further investments in biotechnology companies developing novel therapeutics for rare and complex liver diseases.
Published: 24 May 2026
Explore BasketAntiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.
Published: 16 November 2025
Explore BasketM&A Activity Overview | Pharma Biotech Investments
Merck's $9.2 billion acquisition of Cidara Therapeutics aims to bolster its antiviral portfolio ahead of the Keytruda patent expiration. This strategic purchase signals a broader investment opportunity in biotech firms with advanced clinical assets, positioning them as attractive targets for major pharmaceutical companies.
Published: 15 November 2025
Explore BasketTargeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: 11 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Progress & Trials
Clinical trial outcomes and regulatory updates are primary value drivers; positive readouts can boost interest, while negative news can cause sharp declines.
Drug Development Focus
The company focuses on oral antivirals with potential broad application, but development is lengthy and subject to regulatory scrutiny and competition.
Market Dynamics and Risks
A relatively small market capitalisation implies higher volatility and funding dependence; investors should weigh the upside against the risk of dilution and trial setbacks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
